New eye injection targets two causes of vision loss in wet AMD
NCT ID NCT05456828
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called ASKG712 in 56 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and works by blocking two proteins that fuel abnormal blood vessel growth. The main goals were to check safety and how the drug moves through the body, with some early looks at vision outcomes. The trial has been completed, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASKG712 (a protein that blocks two growth factors involved in abnormal blood vessel growth in the eye)
What this could lead to
If successful, this could lead to a new treatment option for wet age-related macular degeneration that targets two pathways at once, potentially offering better or longer-lasting vision protection.
What could go wrong
This is an early Phase 1/2a study with only 56 participants, so safety and effectiveness are not yet proven. The treatment is injected directly into the eye, which carries risks like infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, China